Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Titel:
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
Auteur:
Kollmannsberger, Christian Hurwitz, Herbert Bazhenova, Lyudmila Cho, Byoung Chul Hong, David Park, Keunchil Reckamp, Karen L. Sharma, Sunil Der-Torossian, Hirak Christensen, James G. Faltaos, Demiana Potvin, Diane Tassell, Vanessa Chao, Richard Shapiro, Geoffrey I.